Virginia family of eight stuck in Colorado after 16-year-old son’s ‘mono’ turned out to be leukemia 

0
11


Marshall Thomas, 16, of Suffolk, Virginia, was diagnosed with B-cell acute lymphoblastic leukemia on Saturday in Colorado after doctors previously believe he had mononucleosis.

Related Links:

This study identified risk factors for TH-ED in a large cohort of patients with APL, which enriched clinical information on identifying patients at high risk of TH-ED.

Publication date: Available online 1 August 2019Source: Stem Cell ReportsAuthor(s): Juan Bautista Menendez-Gonzalez, Milica Vukovic, Ali Abdelfattah, Lubaid Saleh, Alhomidi Almotiri, Leigh-anne Thomas, Aloña Agirre-Lizaso, Aleksandra Azevedo, Ana Catarina Menezes, Giusy Tornillo, Sarah Edkins, Kay Kong, Peter Giles, Fernando Anjos-Afonso, Alex Tonks, Ashleigh S. Boyd, Kamil R. Kranc, Neil P. RodriguesSummarySubversion of transcription factor (TF) activity in hematopoietic stem/progenitor cells (HSPCs) leads to the development of therapy-resistant leukemic stem cells (LSCs) that drive fulminant acute myeloid leukemia…

Conditions:   Chronic Lymphocytic Leukemia;   Waldenstrom Macroglobulinemia;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma Interventions:   Drug: Ibrutinib;   Drug: LY3214996 Sponsors:   Dana-Farber Cancer Institute;   Eli Lilly and Company Not yet recruiting

Source: ClinicalTrials.govCategory: Research Source Type: clinical trials

Condition:   Chronic Myeloid Leukemia Intervention:   Drug: Ponatinib Sponsor:   Fundación Teófilo Hernando, Spain Recruiting

Source: ClinicalTrials.govCategory: Research Source Type: clinical trials

Conditions:   Chronic Lymphocytic Leukemia;   Waldenstrom Macroglobulinemia;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma Interventions:   Drug: Ibrutinib;   Drug: LY3214996 Sponsors:   Dana-Farber Cancer Institute;   Eli Lilly and Company Not yet recruiting

Source: ClinicalTrials.govCategory: Research Source Type: clinical trials

Condition:   Chronic Myeloid Leukemia Intervention:   Drug: Ponatinib Sponsor:   Fundación Teófilo Hernando, Spain Recruiting

Source: ClinicalTrials.govCategory: Research Source Type: clinical trials

In conclusion, given the poor outcome and the newly reported evidence of PD-L1 expression in patients with PBL, further exploration of check point inhibitor therapy is warranted.

Publication date: Available online 1 August 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Evandro D. Bezerra, Megan Othus, Carole Shawn, Mary-Elizabeth Percival, Kelda Gardner, Roland B. Walter, Pamela S. Becker, Paul C. Hendrie, Elihu H. Estey

ConclusionA high LHR at diagnosis is associated with a higher risk of lymphoma progression or death. Automated image analysis is a new tool that can overcome technical limitations of by microarray samples in lymphomas with high intratumor heterogeneity.



Source link